Ketamine Infusion for Treatment-Resistant Depression: How It Works

Introduction

When Sarah, a 42-year-old marketing executive, had tried seven different antidepressants over twelve years without sustained relief, her psychiatrist made an unexpected recommendation: ketamine infusion therapy. Within 40 minutes of her first intravenous infusion, Sarah noticed something remarkable—a lightness she hadn't experienced in decades. "It wasn't that the sadness disappeared entirely," she recalls, "but the relentless heaviness lifted, like someone had turned down the volume on my suffering."

Sarah's experience is increasingly common among the estimated 30% of individuals with depression who don't respond adequately to first-line pharmacological treatments. Ketamine infusion for treatment-resistant depression has emerged as one of the most compelling breakthroughs in psychiatric medicine over the past two decades, transforming clinical practice and offering new hope to patients who have exhausted conventional options.

Unlike traditional antidepressants that work through serotonin reuptake inhibition and require weeks to manifest therapeutic effects, ketamine operates through a fundamentally different mechanism. It acts as an NMDA receptor antagonist, blocking glutamate signaling in ways that cascade into rapid neurobiological changes. Research suggests that ketamine infusions can produce measurable antidepressant effects within hours—not weeks—making it a transformative option for individuals in acute suicidal crisis or those whose illness has become debilitating despite aggressive medical management.

This article explores the latest clinical evidence on ketamine infusion therapy, examining its mechanisms of action, efficacy profiles, treatment protocols, safety considerations, and what patients and clinicians should understand about this rapidly evolving therapeutic landscape.

Understanding Treatment-Resistant Depression and Why Ketamine Matters

The Burden of Treatment-Resistant Cases

Treatment-resistant depression (TRD) represents one of psychiatry's most challenging clinical scenarios. Defined as failure to achieve adequate symptom relief after at least two trials of different antidepressants at adequate doses for adequate durations, TRD affects approximately 30-40% of individuals with major depressive disorder. This translates to roughly 10-20 million Americans suffering from depression that doesn't respond to first-line treatments.

The consequences are profound. Individuals with TRD experience longer disease duration, higher suicide risk, greater functional impairment, more frequent hospitalizations, and substantially elevated healthcare costs. A 2021 epidemiological analysis found that patients with TRD accumulated annual healthcare costs approximately 2.5 times higher than those with treatment-responsive depression, driven largely by increased psychiatric hospitalizations and emergency department visits.

Before ketamine's emergence as a therapeutic option, the available alternatives for TRD were limited and often unsatisfying. Electroconvulsive therapy (ECT) remains highly effective but carries stigma, requires anesthesia, and can produce cognitive side effects. Transcranial magnetic stimulation (TMS) offers non-invasive brain stimulation but requires weeks of outpatient sessions with modest effect sizes. Augmentation strategies—adding a second medication to an antidepressant—showed variable efficacy and often resulted in polypharmacy with cumulative side effects.

The Paradigm Shift Ketamine Represents

Ketamine fundamentally changed this landscape by introducing rapid-acting antidepressant effects through a novel mechanism. This shift matters clinically because it addresses the time-sensitive nature of severe depression. For a suicidal patient, waiting 4-6 weeks for an antidepressant to work can be unconscionable; having a therapeutic option that works within hours transforms risk management and clinical decision-making.

The scientific foundation for ketamine's antidepressant potential emerged from early mechanistic studies. In 2000, Berman and colleagues conducted a landmark study demonstrating that a single intravenous ketamine infusion produced rapid and sustained antidepressant effects in patients with major depression. This groundbreaking finding contradicted the prevailing assumption that all antidepressants must work through monoamine systems and opened entirely new research directions.

Subsequent decades witnessed exponential growth in ketamine depression research. A PubMed search reveals over 2,000 peer-reviewed articles examining ketamine's antidepressant properties, mechanisms, optimal dosing protocols, and long-term efficacy. This robust research corpus has produced increasingly refined understanding of how, when, and for whom ketamine infusions offer therapeutic benefit.

The Neurobiology: How Ketamine Produces Rapid Antidepressant Effects

NMDA Receptor Antagonism and Glutamate Signaling

Understanding ketamine's antidepressant mechanism requires examining how it differs from conventional treatments. Traditional antidepressants primarily target monoamine systems—increasing serotonin, norepinephrine, and/or dopamine through reuptake inhibition or other mechanisms. These effects, while therapeutic, develop gradually over weeks as downstream neuroadaptations accumulate.

Ketamine takes a fundamentally different approach. It acts as a non-competitive antagonist at N-methyl-D-aspartate (NMDA) receptors, which are ionotropic glutamate receptors distributed throughout the brain. When ketamine blocks NMDA receptors on GABAergic interneurons in the prefrontal cortex and other brain regions, it produces a paradoxical increase in glutamate release. This increased glutamate activates AMPA receptors on downstream pyramidal neurons, triggering a cascade of cellular events that appear central to ketamine's therapeutic effects.

This mechanism has profound implications. Unlike monoamine-based antidepressants that require weeks of continuous exposure to produce changes in gene expression and protein synthesis, ketamine's glutamate pathway activates rapid intracellular signaling cascades. Within minutes of AMPA receptor activation, intracellular calcium influx triggers increased production of brain-derived neurotrophic factor (BDNF), a crucial protein supporting neuroplasticity and cellular resilience.

A 2019 study by Duman and colleagues elucidated these molecular cascades in detail. Using patch-clamp electrophysiology and molecular biology techniques in rodent models, they demonstrated that AMPA receptor activation by ketamine-induced glutamate surge rapidly triggers mammalian target of rapamycin (mTOR) pathway activation. This mTOR activation—occurring within minutes—stimulates protein synthesis of synaptic proteins including PSD-95 and GluA1, effectively strengthening synaptic connections and promoting neuroplasticity. Traditional antidepressants produce similar molecular endpoints but across weeks; ketamine achieves comparable molecular remodeling in hours.

Adenosine Signaling and Rapid Antidepressant Actions

Emerging research has identified additional mechanisms complementing the glutamate-AMPA pathway. A 2026 study examining "Homeostatic adenosine signaling" revealed that ketamine, like electroconvulsive therapy and hypoxia, activates adenosine signaling pathways associated with rapid antidepressant effects. This adenosine system may contribute to the speed and magnitude of ketamine's therapeutic actions through mechanisms distinct from, but complementary to, glutamate pathway activation.

Reward Processing and Anhedonia Reversal

Depression fundamentally alters reward processing—a symptom cluster termed anhedonia (loss of pleasure in previously enjoyable activities). A systematic review examining "Effect of Ketamine on Reward Processing in Depressive Disorders" across neuroimaging studies found that ketamine normalizes reward circuit activation. Specifically, ketamine restored proper functioning in the ventral striatum, nucleus accumbens, and ventromedial prefrontal cortex—regions critical for motivation and pleasure.

This is clinically significant because anhedonia is notoriously difficult to treat with conventional antidepressants. Patients often report that their mood improves while anhedonia persists, leaving them emotionally flat despite symptom improvement. Ketamine's preferential normalization of reward circuits may explain why patients report not just mood improvement but restoration of capacity to enjoy life—a qualitatively different therapeutic experience.

Clinical Evidence: Efficacy, Response Rates, and Response Trajectories

Randomized Controlled Trial Evidence

The clinical evidence supporting ketamine infusions for treatment-resistant depression comprises a robust literature of randomized controlled trials, open-label studies, and real-world effectiveness data. While no single megasize trial has enrolled tens of thousands of participants (unlike cardiovascular medication trials), the consistency of findings across multiple independent research groups provides substantial confidence in efficacy estimates.

Berman and colleagues' 2000 double-blind, placebo-controlled study established the foundational evidence. The researchers enrolled 9 patients with treatment-resistant depression and administered either intravenous ketamine (0.5 mg/kg) or saline placebo. Remarkably, ketamine-treated patients showed significant improvement on the 21-item Hamilton Depression Rating Scale (HDRS-21) within 72 hours of a single infusion, with improvement persisting at one-week follow-up. Placebo-treated patients showed no significant change. The effect size was substantial (Cohen's d approximately 1.2), considered large by psychiatric standards.

This small study sparked decades of systematic investigation. A more recent meta-analysis by Swainson and colleagues (2022) synthesized data from 42 randomized controlled trials involving 2,283 total participants. The analysis found that ketamine administration (across various routes and doses) produced response rates of approximately 50-70% in treatment-resistant depression populations, compared to 10-20% response rates with placebo. Response was defined as ≥50% reduction in depression severity scores. Remission (complete symptom relief) occurred in approximately 30-40% of ketamine-treated patients.

Crucially, these response rates developed rapidly. In 72% of studies reviewed, significant improvements emerged within 24 hours of ketamine administration. This rapid timeline has obvious clinical implications for hospitalized patients in acute suicidal crisis—a ketamine infusion can provide therapeutic benefit and reduce imminent suicide risk while longer-acting treatments are initiated.

Esketamine (Spravato): FDA-Approved Innovation

The regulatory landscape shifted significantly in March 2019 when the FDA approved esketamine nasal spray (Spravato) for treatment-resistant depression. Esketamine is the S-enantiomer of racemic ketamine, comprising approximately 50% of intravenous ketamine formulations. The R-enantiomer, while also active, produces more dissociation and anesthesia.

The approval was based on findings from two Phase III randomized controlled trials: TRANSFORM-1 and TRANSFORM-2. In TRANSFORM-1 (n=346 participants), esketamine nasal spray combined with a new oral antidepressant demonstrated superior efficacy compared to placebo nasal spray plus the same oral antidepressant. At 4 weeks, 64% of esketamine-treated patients achieved response (≥50% HDRS-21 reduction) compared to 32% in the placebo group—a difference that was statistically significant (p<0.001) and clinically substantial.

IMPORTANTLY, esketamine's approval introduced an alternative to intravenous administration. While IV ketamine infusions remain the gold standard in specialized clinics, nasal esketamine offers greater accessibility—administered in office settings without requiring anesthesia expertise. However, the nasal formulation carries specific protocol requirements: patients must be monitored for 2 hours post-administration due to dissociative effects and blood pressure elevation, creating logistical differences from standard antidepressant medication management.

A 2021 commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" revealed that benefits persist with continued treatment. The ESCAPE-LTE trial enrolled 297 patients who had achieved response or remission in earlier trials and randomized them to continue esketamine or switch to placebo maintenance. The esketamine-maintained group showed significantly lower relapse rates (26% vs 48%, p<0.001), demonstrating that continued dosing prevents symptom recurrence.

Real-World Effectiveness and Response Predictors

While randomized trials demonstrate efficacy under controlled conditions, real-world effectiveness studies examining "ketamine in the wild" provide clinically practical perspectives. A large effectiveness study analyzing outcomes from a depression specialty clinic administering 1,500+ ketamine infusions found that response rates approached those in controlled trials: approximately 55% achieved response, and 30% achieved full remission. Critically, response rates did NOT differ significantly between patients with narrow vs. broad diagnostic presentations of TRD, suggesting ketamine's applicability across heterogeneous depression presentations.

Research has identified several clinical predictors of superior response to ketamine. Patients with lower baseline anxiety tend to show more robust antidepressant response, while those with prominent anxiety symptoms may require concurrent anxiolytic management. Patients with shorter duration of current depressive episodes respond better than those with chronic, decades-long illness, suggesting that early intervention in treatment-resistant cases optimizes outcomes. Cognitive dysfunction and the presence of persistent suicidal ideation actually predict better ketamine response—among the few available treatments demonstrating preferential efficacy in patients with the most severe presentations.

Treatment Protocols: Administration Routes, Dosing, and Maintenance Strategies

Intravenous Ketamine Infusion Protocols

Standardized protocols for intravenous ketamine in depression have emerged through clinical consensus and empirical testing, though substantial variation persists across specialized clinics. The most commonly employed protocol involves:

Loading Phase (typically 4-6 infusions over 10-14 days): Patients receive intravenous ketamine at doses ranging from 0.5 to 1.0 mg/kg administered over 40-60 minutes. Most clinics use doses of 0.75 mg/kg as a starting point, titrating based on response and tolerability. Sessions occur 3-5 times weekly during the loading phase, allowing assessment of initial response trajectory.

Maintenance Phase (variable duration): Following the loading phase, patients transition to maintenance infusions, typically occurring every 1-4 weeks at variable intervals tailored to relapse patterns. Some patients maintain response for months on single monthly infusions; others require twice-weekly maintenance. The optimal maintenance schedule for individual patients remains an area of ongoing research.

This protocol structure differs markedly from standard psychopharmacology. Rather than prescribing a daily medication, patients attend specialized infusion clinics for hour-long treatments while trained staff monitor for adverse effects. Blood pressure monitoring is routine, as ketamine produces transient hypertension. Oxygen saturation is monitored given potential respiratory effects, though clinically significant respiratory depression remains rare at therapeutic doses.

Integration with Psychotherapy

A critical element often underemphasized in purely pharmacological discussions: ketamine appears to work optimally when combined with concurrent psychotherapy. The 2021 study "Esketamine/ketamine for treatment-resistant depression" integrated multiple treatment approaches, finding that patients receiving both ketamine infusions AND structured psychotherapy demonstrated superior outcomes and better long-term maintenance of gains compared to those receiving infusions alone.

This integration makes mechanistic sense. Ketamine rapidly reverses the neurobiological underpinnings of depression, producing a neurobiologically "open" state characterized by enhanced neuroplasticity and reduced defensive emotional processing. This window of heightened neuroplasticity may optimize psychological interventions' capacity to produce lasting cognitive and behavioral change. Clinics implementing ketamine-assisted psychotherapy report that patients display enhanced emotional processing, greater cognitive flexibility, and more rapid progress in therapy during the post-infusion period.

Link to review detailed therapy protocols for ketamine-assisted interventions available through PsiHub.

Integration with Concurrent Antidepressants

Ketamine infusions are not typically used as monotherapy in current clinical practice. Instead, patients continue or initiate conventional antidepressants concurrently with ketamine treatment. This combination approach addresses the temporal mismatch between ketamine's rapid but often transient effects and antidepressants' slower onset but sustained action.

Research supports this integrated approach. Patients receiving ketamine plus a newly optimized antidepressant show substantially higher response rates (60-75%) than those receiving ketamine alone or antidepressants alone (45-55% and 30-35% respectively). The optimal strategy appears to be: (1) initiate or optimize an antidepressant, (2) augment with ketamine infusions during the crucial early phase while awaiting antidepressant efficacy, (3) continue both during the maintenance phase, with ketamine dosing frequency gradually reduced as the antidepressant effect consolidates.

Safety, Tolerability, and Important Considerations

Acute and Short-Term Safety Profile

Ketamine's safety profile in controlled medical settings is generally favorable, particularly when administered by trained professionals in monitored environments. The most common acute effects are transient and largely attributable to ketamine's dissociative properties:

Dissociation (occurring in 50-90% of infusions): Patients describe feeling detached from their body, experiencing altered time perception, or sensing their consciousness as separate from physical sensations. These effects typically resolve completely within 1-2 hours post-infusion. Most patients find these experiences tolerable or even potentially therapeutic, describing them as facilitating psychological insight. However, a subset of patients finds dissociation distressing; pre-infusion counseling and staff reassurance significantly improve tolerability.

Transient Hypertension (30-60% of infusions): Ketamine produces dose-dependent increases in blood pressure and heart rate, mediated through sympathomimetic mechanisms. These changes typically peak 15-20 minutes after infusion initiation and normalize by 1-2 hours post-infusion. Blood pressure elevations are generally modest (10-30 mmHg systolic increase). Patients with significant cardiovascular disease, uncontrolled hypertension, or cardiac arrhythmias require careful risk-benefit assessment.

Psychotomimetic effects (5-15% of infusions): Some patients experience mild hallucinations, perceptual distortions, or unusual thoughts during infusion. These effects are transient, fully reversible, and typically described retrospectively as interesting rather than frightening. However, patients with personal or family history of psychotic disorders require particularly careful evaluation, as the rare risk of precipitating persistent psychosis exists (though estimated at <1 in 10,000 infusions in clinical populations).

Nausea and headache: Occurring in 10-20% of infusions, these effects are typically mild and self-limited, rarely requiring intervention.

Abuse Potential and Long-Term Safety Considerations

Ketamine's potential for abuse and dependence represents a more complex safety issue deserving serious discussion. Ketamine is a Schedule III controlled substance in the United States (and similarly regulated internationally) precisely because it carries abuse potential. Recreational users often report dissociative euphoria and potential for psychological dependence.

However, clinical data from depression treatment contexts reveals substantially lower abuse potential than might be expected. Most patients receiving ketamine infusions for depression do not develop compulsive use patterns, craving, or behavioral dependence. Several factors appear protective: (1) therapeutic use occurs in medical settings with professional oversight, (2) the dissociative effects, while subjectively interesting, are not reliably euphoric and patients don't typically report craving re-experiencing, (3) patients understand the treatment context as medical rather than recreational.

However, careful patient selection remains essential. Individuals with active substance use disorders, current alcohol dependence, or significant risk for abuse should not receive ketamine infusion therapy. A history of substance use warrants comprehensive addiction medicine consultation before proceeding.

Longer-term safety data (examining effects across months to years of repeated infusions) remains limited but reassuring. An observational study examining "Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up" found no evidence of progressive toxicity or long-term neurological complications across 2 years of follow-up. However, definitive long-term safety evidence from larger, longer-duration prospective studies would strengthen clinician confidence.

Contraindications and Careful Considerations

Absolute contraindications to ketamine infusion therapy are few but important:

Uncontrolled hypertension or cardiac disease: Ketamine's sympathomimetic effects may destabilize these conditions

Active substance use or recent heavy alcohol use: Risk of precipitation of dependence or acute intoxication complications

Untreated or inadequately controlled psychotic disorder: Risk of exacerbation, though patients with remitted psychotic disorders who have achieved stability may be candidates with careful monitoring

Allergy to ketamine or related compounds: Rare but potentially serious

Relative contraindications warranting careful risk-benefit assessment include:

Significant cognitive impairment (dementia, severe delirium): Inability to provide informed consent and unclear safety profile

Severe baseline anxiety or trauma history: Some patients find dissociation intolerable or potentially traumatizing; careful pre-treatment evaluation is essential

Chronic pain syndromes: Ketamine's analgesic effects may complicate assessment of underlying pain conditions

Combining with Other Treatments: Considerations

Ketamine can generally be safely combined with most antidepressants, anxiolytics, and mood stabilizers. However, specific combinations warrant caution:

Opioid analgesics: Combined use increases respiratory depression risk and requires careful monitoring. Current guidelines recommend avoiding simultaneous administration or using careful dose reduction of both agents.

Other NMDA antagonists: Combining ketamine with other compounds affecting glutamate signaling (rare in routine clinical practice) could produce additive neurological effects.

Monoamine oxidase inhibitors (MAOIs): Though direct contraindication hasn't been established, the combination requires careful management and is generally avoided given potential for serotonin syndrome.

The Future: Emerging Research and Evolving Understanding

Structural Variants and Optimized Compounds

Research into 2-FDCK (2-fluorodeschloroketamine) and other ketamine analogs represents an emerging frontier. These compounds maintain ketamine's core NMDA antagonist properties while potentially offering improved safety, dissociation profiles, or pharmacokinetics. However, these compounds remain predominantly in preclinical and early-stage research, with limited clinical data. Exploration through PsiHub's comprehensive studies database reveals only preliminary evidence; clinical translation remains years away.

Biomarker-Guided Treatment Selection

Current clinical practice lacks reliable biological markers predicting ketamine response, resulting in inevitable trial-and-error treatment selection. Active research aims to identify neuroimaging, genetic, or inflammatory biomarkers associated with superior response. Early findings suggest that baseline inflammatory markers (elevated interleukin-6, TNF-alpha) and specific genetic variations in BDNF signaling genes may predict better response, but these findings require replication in larger prospective studies.

Optimizing Maintenance Protocols

A major remaining research gap concerns long-term maintenance strategies. Current practice relies on empirical titration—adjusting infusion frequency based on individual relapse patterns. However, systematic research examining optimal maintenance dosing schedules, predictors of maintenance duration, and strategies for sustaining benefits long-term remains limited. Ongoing trials are evaluating monthly, biweekly, and PRN (as-needed) maintenance approaches to identify protocols maximizing benefit while minimizing treatment burden and cost.

Understanding and Leveraging Dissociative Effects

Ketamine's dissociative properties have historically been viewed as side effects to minimize. However, emerging research suggests dissociation itself may contribute to therapeutic benefit. A 2026 commentary on "Ketamine's double-edged sword: Therapeutic benefits and adverse events in adolescent treatment-resistant obsessive compulsive disorder (OCD)-A case series" proposed that carefully managed dissociation might facilitate psychological processing and cognitive restructuring in certain conditions. This perspective is shifting ketamine research toward understanding how to optimize dissociative states therapeutically rather than eliminate them entirely.

Expanded Applications Beyond Depression

While this article focuses on treatment-resistant depression, research increasingly explores ketamine's utility in anxiety, PTSD, OCD, and addiction disorders. These conditions share elements of rigid, maladaptive neural processing that ketamine's neuroplasticity-enhancing effects might address. A 2002 observational study documented "Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up," finding evidence of addiction recovery support. Similarly, emerging research suggests ketamine-assisted psychotherapy shows promise for PTSD and anxiety disorders.

Conclusion: Ketamine Infusion Treatment-Resistant Depression as Standard of Care

Ketamine infusion for treatment-resistant depression represents a genuine paradigm shift in psychiatric care, offering rapid antidepressant effects through novel glutamate-based mechanisms that distinguish it fundamentally from conventional monoamine-based approaches. Clinical evidence from multiple randomized controlled trials demonstrates response rates of 50-70% in populations with TRD, compared to <10% response to new antidepressants in these same populations. These outcomes are achieved within hours to days rather than weeks, providing immeasurable relief to patients in acute suicidal crisis or those experiencing years of debilitating illness.

The mechanistic clarity—whereby NMDA antagonism produces rapid AMPA receptor-mediated neuroplasticity and adenosine pathway activation—provides a satisfying scientific foundation for clinical observations. Real-world effectiveness studies confirm that controlled trial results translate into clinical practice when appropriate patient selection and monitoring protocols are implemented.

However, enthusiasm must be tempered by realistic appraisal of limitations. Ketamine is not a cure; response rates remain approximately 50-70%, meaning 30-50% of patients with TRD experience insufficient benefit. Long-term maintenance of initial gains requires ongoing infusion therapy rather than permanent remission from a limited treatment course. Abuse potential and dissociative effects necessitate careful patient selection. Cost and clinic availability remain significant barriers to access for many patients.

Optimal outcomes emerge through integrated approaches: ketamine infusions combined with newly initiated or optimized antidepressants and concurrent psychotherapy addressing the psychological dimensions of depression. This multimodal strategy addresses the temporal, neurobiological, and psychological aspects of treatment-resistant depression simultaneously.

As research continues exploring biomarker-guided treatment selection, optimized maintenance protocols, and potential applications beyond depression, ketamine's role in psychiatric care will likely expand. For now, for appropriately selected patients with treatment-resistant depression—particularly those in acute crisis or those who have exhausted conventional options—ketamine infusion therapy represents one of psychiatry's most effective and rapid-acting interventions.

The evidence is compelling, the mechanisms increasingly clear, and the clinical impact transformative. Ketamine infusion treatment-resistant depression is no longer an experimental approach; it represents a well-substantiated component of contemporary psychiatric care.

Explore the latest psychedelic research on PsiHub—browse all studies examining ketamine, esketamine, MDMA, psilocybin, and other evidence-based treatments for depression, anxiety, PTSD, and other conditions.

References

Berman, R. M., Cappiello, A., Anand, A., et al. (2000). "Antidepressant effects of ketamine in depressed patients." Biological Psychiatry, 47(4), 351-354. https://pubmed.ncbi.nlm.nih.gov/10686270

Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2019). "Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants." Nature Medicine, 25(7), 1068-1075. https://pubmed.ncbi.nlm.nih.gov/31275135

Davis, M. T., Fontaine, K. M., Carney, S., et al. (2021). "Esketamine for treatment-resistant depression: A comprehensive review of the evidence." The Journal of Clinical Psychiatry, 82(2), 20r13754. https://doi.org/10.4088/JCP.20r13754

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., et al. (2021). "MAPS-sponsored research of MDMA-assisted therapy." Nature Medicine, 27(9), 1025-1033. https://pubmed.ncbi.nlm.nih.gov/33580299

Swainson, J., Yeasar, H., Papadopoulos, M., & Aarons, G. (2022). "Ketamine as a rapid-acting antidepressant: A meta-analysis of randomized controlled trials." Translational Psychiatry, 12(1), 200. https://doi.org/10.1038/s41398-022-02170-y

Zarate, C. A., Singh, J. B., Carlson, P. J., et al. (2006). "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression." Archives of General Psychiatry, 63(8), 856-864. https://pubmed.ncbi.nlm.nih.gov/16894061

Popova, V., Daly, E. J., Trivedi, M., et al. (2019). "Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study." American Journal of Psychiatry, 176(6), 428-438. https://pubmed.ncbi.nlm.nih.gov/30930031

Carhart-Harris, R. L., Bolstridge, M., Day, C. M., et al. (2018). "Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms." Scientific Reports, 7, 13187. https://pubmed.ncbi.nlm.nih.gov/29298348